Recently, abnormal expression of a great variety of adhesion molecules has been reported in malignancy. Of these adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) has been suggested to play an important role in the process of tumor invasion and distant metastasis. The purpose of this investigation was to assess the peripheral blood levels of soluble ICAM-1and the effect ofcytotoxic therapy upon these circulating molecules in a cohort of patients with lung cancer. This study comprised 19 lung cancer patients hospitalized in our institution (males 16 and females 3, mean age 60 years old). Serum concentration of soluble ICAM-1was measured using a commercially available enzyme immunoassaytest kit. These measurements were done before the initiation of any therapy and on day 5 of chemotherapy. Samples taken from healthy volunteers were available for comparison. Soluble ICAM-1serum concentration was significantly higher (p<0.0001) in the cancer patients as compared to that of the control group. Serum levels ofIGAM-1 were more significantly (p<0.02) elevated in patients with advanced stages of disease. This study suggests the presence of an increased expression of circulating adhesion molecules in lung cancer.
Introduction
Intercellular adhesion molecule-1 (ICAM-1) is a 74-1 14 KDatransmembrane glycoprotein that belongs to the immunoglobulin supergene family (1). ICAM-1together with its integrin ligands the leukocyte function-related antigen-1 (LFA-1, CD1 la/CD18) and the macrophage antigen Mac-1 (CD1 lb/ CD18), plays important role during the immuneresponse in inflammatory and neoplastic processes (2, 3). ICAM-1medi-ates the adherence of leukocytes to vascular endothelial cells and their subsequent emigration into the sites of inflammation (4). The molecular interaction between ICAM-1 and LFA-1 is a crucial step for triggering the signals leading to cytotoxic and helper lymphocyte functions (5, 6). ICAM-1 has been also found to play significant roles in tumorigenesis and metastatic spread of malignant tumors (7, 8). ICAM-1has been isolated from most tissues and cells. It is expressed on the surface of normal hematopoietic and nonhematopoietic cells, vascular endotheliumand in a great number of tumors (9) (10) (11) (12) (13) (14) . This expression of ICAM-ls can be upregulated by inflammatory cytokines such as gamma-interferon, tumor necrosis factor alpha, and by lipopolysaccharides (15, 16) . The significance of the in situ expression of ICAM-1 in malignant tumors remains controversial. While local induction of ICAM-1is related to most susceptibility of tumor cells to lysis by the host cellular immune system, increased histological expression of this adhesion molecule is correlated with disease progression and poor prognosis in some patients, particularly in patients with malignant melanoma (17, 1 8).
ICAM-1in Lung Cancer Patients
The objective of present study was to investigate the serum concentration of ICAM-1 before and after systemic administration of cisplatin-based anticancer therapy and its relation with the clinical stage in patients with lung cancer. To the best of our knowledge, this is the first study to report the levels of circulating ICAM-1 in lung cancer patients.
Materials
and Methods washing , chromogenic solution containing o-phenylenediamine was pipetted into each microplate well and absorbance was read at 490 nmin a microplate reader after stopping the reaction with sulfuric acid. The detection limit of the assay was of 0.3 ng/ml. The intra-assay and the inter-assay coefficient of variations were 2 and 3%, respectively. Values ofICAM-1 in 31 healthy volunteers were available for comparison. In all patients, the adhesion molecule was determined before the initiation of any therapy. In 1 1 patients treated with cisplatinbased combination chemotherapy, ICAM-1 was measured before starting and after completing the administration of the full dose of cytotoxic drugs. Chemotherapeutic agents combination and schedule were as follows: (a) for non-SCLC:cisplatin 80 mg/m2 day 1, mitomycin 8 mg/m2 day 1, vindesine 3 mg/m2 days 1, 8, and 15; (b) for SCLC: cisplatin 80 mg/m2 day 1, etoposide 100 mg/m2 day 1, 3 and 5. Patients were assigned to two groups according to the response to anticancer therapy. Responders showed a 50%or more decrease in the product of the longest perpendicular diameters of measurable tumor lesions lasting at least 4 weeks after chemotherapy. Patients with increased tumor size or with diminution of tumor volumeless than 50%were classified as non-responders. Blood samples were drawn after patients rested in supine position for 30-min. After centrifuging the blood samples at 3,000 rpm for 20-min, the serumfractions were separated in small aliquots and stored at -20°C until use. All blood samples were taken after obtaining written and formal consent from the patients. The investigation was approved by our Institution Ethic Committee and it was carried out in accordance with the stipulations of the Helsinki Declaration.
Statistical analysis
Data are expressed as means±SD, unless otherwise specified. The difference between the means ofvariables was analyzed by the Mann-Whitney U test. The strength of correlation was calculated by the Spearman coefficient of correlation (24) .
Results
There was no significant difference in age and sex between lung cancer patients and healthy controls. Although there were moresmokers amongpatients with lung cancer than in control subjects, there was no significant difference in the serum concentration of ICAM-1between smokers and nonsmokers (data not shown).
The serum concentration ofICAM-1 was significantly higher (p<0.0001) in patients with lung cancer (494.2±33.3 ng/ml vs. 280.2±21.3 ng/ml) than in the healthy control group (Fig. 1) .
For evaluating the influence of clinical progression on the serum expression ofICAM-1 , the patients were assigned to two groups : a group with malignant lesions restricted to one hemitho- Analysis of the serum levels ofICAM-1 in each histological type, adenocarcinoma (5 14.6±62.3 ng/ml), squamous cell carcinoma (586.5+100.1 ng/ml) and small cell carcinoma (592.5±27.5 ng/ml) did not reveal any statistically significant difference among the three histological groups (p=0.3). The administration of combination chemotherapy in 1 1 patients did not significantly change (p=0.6) the serum levels of ICAM-1 (510.8+46.3 ng/ml vs 535.5±52.9 ng/ml). Also there was no significant difference in the serum ICAM-1 levels between nonresponder and responder groups (500.3±71.8 ng/ml vs 516.6±60.3 ng/ml, p=0.5).
Discussion
The Our current preliminary study showed that, the serum concentration ofICAM-1 is elevated even at stage I in lung cancer patients, indicating that stimulating activities for ICAM-1 se- . If this were the case, cancer patients that respond to anticancer treatment might theoretically have a lower concentration of soluble ICAM-1in their serum than those nonresponders to chemotherapy. This potential usefulness of circulating ICAM-1as a marker of response to chemotherapy in patients with malignancy was assessed in the current study. ICAM-1 serum levels were not significantly different between responder and non-responder patients. However, a prospective study with a larger number of patients is required to clarify this issue.
In brief, the results of this investigation suggest the existence of an increased expression and shedding of ICAM-1 in lung cancer and that the serum concentration of ICAM-1is positively correlated with the clinical stage of disease. Serum levels of ICAM-1might not be good indicators of the chemotherapy response in these patients. 
